EXACT SCIENCES CORP 4

President and CEO Kevin T. Conroy received and then fully cashed out of 1,397,738+ shares and associated options/RSUs of Exact Sciences Corp. at $105.00 per share in connection with the Abbott merger.

On March 23, 2026, President and CEO Kevin T. Conroy reported the cash‑out and cancellation of his equity holdings in Exact Sciences Corp. in connection with the closing of its merger with Abbott Laboratories at $105.00 per share. A new award of 119,312 shares of common stock was reported (likely the vesting and conversion of performance/other equity immediately prior to the merger), after which all 1,397,738 directly held common shares, plus indirect holdings in a 401(k) plan and several Grantor Retained Annuity Trusts, were converted into the right to receive the $105.00 per‑share cash merger consideration. In addition, multiple tranches of stock options with exercise prices of $21.68, $44.37, $92.62, and $98.18 per share, as well as several restricted stock unit awards, were cancelled and converted into cash based on the spread between their exercise prices (for options) or full $105.00 per share (for RSUs), leaving the reporting person with zero share ownership in Exact Sciences post‑transaction as the company became a wholly‑owned subsidiary of Abbott.

Filing Facts

CIK

1124140

Ticker

EXAS

Form

4

Source Type

sec

Accession

0001193125-26-118755

Alert Tier

7